Cargando…

The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature

AIMS: The objective of this article is to summarize the state of the literature surrounding the use of ketamine as a neuroprotective agent following cardiac arrest. METHODS: Five electronic databases were used to search for studies related to the use of ketamine for neuroprotection following cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ornowska, Marlena, Wormsbecker, Andrew, Andolfatto, Gary, Leung, Tim S., Khan, Idan, Medvedev, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804040/
https://www.ncbi.nlm.nih.gov/pubmed/36184822
http://dx.doi.org/10.1111/cns.13983
_version_ 1784862014476124160
author Ornowska, Marlena
Wormsbecker, Andrew
Andolfatto, Gary
Leung, Tim S.
Khan, Idan
Medvedev, George
author_facet Ornowska, Marlena
Wormsbecker, Andrew
Andolfatto, Gary
Leung, Tim S.
Khan, Idan
Medvedev, George
author_sort Ornowska, Marlena
collection PubMed
description AIMS: The objective of this article is to summarize the state of the literature surrounding the use of ketamine as a neuroprotective agent following cardiac arrest. METHODS: Five electronic databases were used to search for studies related to the use of ketamine for neuroprotection following cardiac arrest. This search was performed once in May 2020, and an updated search was conducted in May 2021 and March 2022. RESULTS: All searches combined retrieved 181 results; no clinical trials were identified. As such, the authors were limited to writing a scoping review of the literature rather than a systematic review. CONCLUSIONS: The current state of the literature describes the mechanism of action of ketamine as a neuroprotective agent through its action as an NMDA antagonist. There is evidence of its efficacy as a neuroprotective agent in preclinical models of cardiac arrest. Current published clinical work supports the use of ketamine ameliorating neurologic outcomes in other conditions such as epilepsy, traumatic brain injury, and depression. The current state of the literature is reflective of the notion that the use of ketamine following cardiac arrest may result in improved neurologic outcomes. Future research directions should focus on the use of ketamine as a possible clinical intervention following cardiac arrest.
format Online
Article
Text
id pubmed-9804040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98040402023-01-04 The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature Ornowska, Marlena Wormsbecker, Andrew Andolfatto, Gary Leung, Tim S. Khan, Idan Medvedev, George CNS Neurosci Ther Original Articles AIMS: The objective of this article is to summarize the state of the literature surrounding the use of ketamine as a neuroprotective agent following cardiac arrest. METHODS: Five electronic databases were used to search for studies related to the use of ketamine for neuroprotection following cardiac arrest. This search was performed once in May 2020, and an updated search was conducted in May 2021 and March 2022. RESULTS: All searches combined retrieved 181 results; no clinical trials were identified. As such, the authors were limited to writing a scoping review of the literature rather than a systematic review. CONCLUSIONS: The current state of the literature describes the mechanism of action of ketamine as a neuroprotective agent through its action as an NMDA antagonist. There is evidence of its efficacy as a neuroprotective agent in preclinical models of cardiac arrest. Current published clinical work supports the use of ketamine ameliorating neurologic outcomes in other conditions such as epilepsy, traumatic brain injury, and depression. The current state of the literature is reflective of the notion that the use of ketamine following cardiac arrest may result in improved neurologic outcomes. Future research directions should focus on the use of ketamine as a possible clinical intervention following cardiac arrest. John Wiley and Sons Inc. 2022-10-02 /pmc/articles/PMC9804040/ /pubmed/36184822 http://dx.doi.org/10.1111/cns.13983 Text en © 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Ornowska, Marlena
Wormsbecker, Andrew
Andolfatto, Gary
Leung, Tim S.
Khan, Idan
Medvedev, George
The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
title The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
title_full The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
title_fullStr The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
title_full_unstemmed The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
title_short The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
title_sort use of ketamine as a neuroprotective agent following cardiac arrest: a scoping review of current literature
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804040/
https://www.ncbi.nlm.nih.gov/pubmed/36184822
http://dx.doi.org/10.1111/cns.13983
work_keys_str_mv AT ornowskamarlena theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT wormsbeckerandrew theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT andolfattogary theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT leungtims theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT khanidan theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT medvedevgeorge theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT ornowskamarlena useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT wormsbeckerandrew useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT andolfattogary useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT leungtims useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT khanidan useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature
AT medvedevgeorge useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature